Avizakimab, formerly known as BOS161721, represents a promising clinical approach to treating autoimmune conditions . This monoclonal agent selectively targets IL-18 , a crucial signaling molecule implicated https://alvinqmct524818.blog5.net/93143101/avizakimab-a-thorough-analysis-into-bos161721-s-promise